Encompass Health (EHC)
(Delayed Data from NYSE)
$94.73 USD
-0.36 (-0.38%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $94.31 -0.42 (-0.44%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Price, Consensus and EPS Surprise
EHC 94.73 -0.36(-0.38%)
Will EHC be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for EHC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EHC
Why Encompass Health (EHC) is a Top Value Stock for the Long-Term
Why Encompass Health (EHC) is a Top Value Stock for the Long-Term
EHC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Encompass Health (EHC) is a Top Growth Stock for the Long-Term
Why Encompass Health (EHC) is a Top Growth Stock for the Long-Term
Encompass Health Opens 9th Hospital in SC: More in the Pipeline?
Other News for EHC
Looking Into Encompass Health's Recent Short Interest
HCA Healthcare: Still A Great Play On Long-Term Growth And Valuation
Election 2024: Where To Put Your Money Ahead of the Vote
Encompass Health price target raised by $10 at RBC Capital, here's why
Guggenheim SMid Cap Value Fund Q2 2024 Commentary